Wunderlich’s syndrome associated with anticoa gulant treatment, heart failure, and post‐radiation vasculopathy
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2019, Vol 4, Issue 2
Abstract
Background: Wunderlich’s syndrome (WS) is an extremely rare condition, characterised by spontaneous haemorrhage into the subcapsular, perirenal, and retroperitoneal spaces. The most common cause is renal angiomyolipoma. Classic symptoms, such as acute flank pain, flank mass, and hypovolemic shock, known as Lenk’s triad, have limited sensitivity and specificity for detecting WS. High mortality may be related to the difficulties in diagnosis, poor disease recognition, and non‐specific symptoms and signs. Computed tomography (CT) is the method of choice for the diagnosis of WS. Depending on the severity of symptoms, a conservative or invasive approach is reasonable. Methods and results: We report the case of a 58‐year‐old male with multivalvular heart defect, atrial fibrillation, and exacerbation of chronic heart failure complicated with nontraumatic bleeding into the retroperitoneal space. CT revealed a massive (14x11x26 cm) retroperitoneal and perirenal haematoma. The patient was successfully treated with transfusion of red blood cells, fresh frozen plasma, and intravenous fluids. Simultaneously, heart failure treatment was initiated. In view of the chronic and idiopathic character of the haematoma and successful conservative treatment, there was no indication for surgery. Discussion: Several factors might have contributed to the bleeding. First, the patient was receiving anticoagulant treatment to reduce the risk of arterial thromboembolism in atrial fibrillation. Another possible cause is post‐radiation vasculopathy, an adverse effect of previous radiation therapy for malignant granuloma. The third factor which could have contributed to bleeding was the exacerbation of chronic heart failure and pulmonary hypertension. JRCD 2019; 4 (2): 51-55.
Authors and Affiliations
Adam Pytlewski, Mateusz Siwek, Leszek Drabik, Miłosz Delikat, Dawid Śmietana, Ewa Sobieraj, Paweł Iwaszczuk, Wojciech Płazak
Keywords
Related Articles
- EP ID EP630624
- DOI 10.2041/jrcd.vol4no2.370
- Views 115
- Downloads 0
JRCD is now an open‑access journal and also accepts high‑quality papers beyond the field of rare cardiovascular diseases and disorders
n/a
Current views on the use of interferons in the treatment of polycythaemia vera
Interferon alpha is a molecule associated with stimulation of immune system cells, resulting in an anti‐proliferative and immunomodulatory effect. It has been demonstrated that interferon reduces the number of platelets,...
World Rare Disease Day – 29th of February 2016 III Conference of Rare Cardiovascular Diseases at John Paul II Hospital in Krakow
The third Conference of Rare Cardiovascular Diseases took place at the John Paul II Hospital in Krakow, Poland on the 29th of February 2016. The conference was organized as part of the World Rare Disease Day 2016 annuall...
Heart in Fabry Disease
Fabry disease is one of the lysosomal storage disorders, that results from progressive multiorgan accumulation of glycoproteins. It is caused by mutations of the GLA gene, which encodes alpha-galactosidase A. The incide...
Pulmonary arterial hypertension: management in specific medical conditions
Pulmonary arterial hypertension (PAH) is a severe and progressive disease. Due to the narrowing of the blood vessels in the lungs, pul- monary vascular resistance and pulmonary pressures increase. This results in reduced...